Alzheimer's disease (AD) is a devastating neurodegenerative disorder characterized by
progressive cognitive decline and memory loss. Early and accurate diagnosis of AD is …

Introduction Clinical proteomics studies of Alzheimer's disease (AD) research aim to identify
biomarkers useful for clinical research, diagnostics, and improve our understanding of the …

Alzheimer's disease is the scourge of the modern, aging world: a costly, damaging disease
that robs the elderly of their ability to function as well as their memories. Three decades of …

Alzheimer's disease (AD) and its related syndromes–especially frontotemporal dementia
(FTD), Lewy body dementia (LBD) and dementias associated with cerebrovascular disease …

Alzheimer's disease (AD) is the most prevalent form of dementia, and the numbers of AD
patients are expected to increase as human life expectancy improves. Deposition of β …

Our current understanding of the molecular changes that drive Alzheimer's disease (AD)
pathogenesis is incomplete. Unbiased, mass spectrometry-based proteomic studies provide …

Biomarker research for Alzheimer's disease (AD) has been growing rapidly over recent
years especially as the number of persons affected by this disease is nearing approximately …

Substantial progress in the understanding of the biology of Alzheimer's disease (AD) has
been achieved over the past decades. The early detection and diagnosis of AD and other …

Alzheimer's disease (AD) is a progressive brain amyloidosis that injures brain regions
involved in memory consolidation and other higher brain functions. Neuropathologically, the …

Mass spectrometry-based proteomics empowers deep profiling of proteome and protein
posttranslational modifications (PTMs) in Alzheimer's disease (AD). Here we review the …